Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size

Healthcare

Vera wraps up $80m series C
Yale-linked Vera has rebranded from Trucode Gene Repair and will use the money to move towards clinical trials.
Daily deal net: January 22, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
NexImmune elects to launch initial public offering
Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.
Bolt Biotherapeutics charges to IPO stage
Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.
Vor Biopharma goes for $150m in IPO
Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.
Verve Therapeutics turns to $94m series B
Novo and GV participated in a round that lifted the Harvard, Broad Institute and Penn-linked heart disease drug developer's overall funding to more than $215m.
Immunocore plots course to $100m IPO
The immunotherapy developer plans to go public in the US having raised $565m since being formed to develop assets of a defunct Oxford spinout.
AltPep unpacks $23.1m round
University of Washington spinout AltPep will use the money to advance work on its lead asset that targets Alzheimer’s disease.

Other News

J-Pharma jacks series D up to $21m
Fidelity provided a $4.8m second tranche after a first close featuring vehicles for Kyushu University and Osaka University.
BlueSphere Bio brings in $45.6m
Pitt spinout BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target size.
Biohaven brings Kleo into the fold
Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.
Immunocore impresses with $75m series C
The Oxford-linked oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.
Johnson & Johnson turns Paige to $100m
Johnson & Johnson Innovation – JJDC has co-led the computational pathology technology provider's series C round to take its total funding to $195m.
Atalanta attains series A
Atalanta Therapeutics has launched out of UMass with $110m in combined series A and partnership funding to develop therapies for neurodegenerative diseases.

Editor's Picks

When worlds collide – CVC interest in spinouts
Steady is the assessment that comes to mind, rather than remarkable, when probing the year-on-year direction of corporate venture capital investment in university spinouts.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
test reg

Login